Oncogenex Pharmaceuticals, Inc. (OGXI): Cindy Jacobs , EVP, CMO of Oncogenex Pharmaceuticals, Inc. sold 1,437 shares on Jun 13, 2016. The Insider selling transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were sold at $1.02 per share for a total value of $1,473.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 15, 2016, Scott Daniel Cormack (President and CEO) sold 4,856 shares at $1.02 per share price.On Mar 16, 2016, Cindy Jacobs (EVP, CMO) sold 3,254 shares at $0.83 per share price.Also, On Mar 16, 2016, John Bencich (CFO) sold 834 shares at $0.83 per share price.
Shares of OncoGenex Pharmaceuticals Inc (OGXI) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.03 points or -2.78% at $1.05 with 2,44,539 shares getting traded. Post opening the session at $1.09, the shares hit an intraday low of $1.02 and an intraday high of $1.1 and the price vacillated in this range throughout the day. The company has a market cap of $31 M and the number of outstanding shares has been calculated to be 2,99,14,226 shares. The 52-week high of OncoGenex Pharmaceuticals Inc is $4.1 and the 52-week low is $0.455.
OncoGenex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has three product candidates in its pipeline: custirsen apatorsen and OGX-225. Of the product candidates in its pipeline custirsen and apatorsen are clinical-stage assets being evaluated in two Phase III studies and five Phase II studies. These product candidates focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments.